You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
九典制藥(300705.SZ):PDX-06獲批開展臨牀試驗
格隆匯 01-09 18:02

格隆匯1月9日丨九典制藥(300705.SZ)公佈,公司於近日收到國家藥品監督管理局簽發的PDX-06的《藥物臨牀試驗批准通知書》,在完成相關準備工作後將開展臨牀試驗研究。

PDX-06為口服非甾體抗炎藥,目前國內外未有該產品處於臨牀試驗階段,國內外尚無該產品獲批上市,亦無相關銷售數據。非甾體類藥物具有止痛和抗炎的特性,是治療關節炎疾病的一線用藥。目前已有百餘種藥品上市,這類藥物主要包括布洛芬、雙氯芬酸、阿司匹林等,劑型包括口服、外用、注射劑等。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account